Results are generally ready within 30 minutes. Photo courtesy of CVS Health

Flu season and cedar fever compounded with the ongoing COVID-19 pandemic is likely to make for a worrisome winter. In an effort to make testing for the novel coronavirus more accessible, CVS is launching rapid-result tests in 21 stores across the state, including four in Houston.

The Rhode Island-based health company announced its COVID-19 testing expansion on October 28, adding that it hopes to offer the service at 1,000 clinics nationwide by the end of the year.

In the Greater Houston area, COVID-19 rapid-result tests are available at the following CVS stores beginning this week:

  • 1410 Crabb River Rd. in Richmond
  • 3505 Center St. in Deer Park
  • 2232 Repsdorph Rd. in Seabrook
  • 23865 FM 1314 in Porter

Test results are usually available within 30 minutes. Rapid-result COVID-19 tests are available at no cost to patients who meet Centers for Disease Control and Prevention criteria, for those with private insurance, or those insured by the U.S. Department of Health and Human Services, notes a release. Read more about testing costs here.

Patients must register in advance at CVS.com in order to obtain a rapid-result test. Tests are also available for patients ages 12-17, but they must have a parent or guardian fill out the testing information. Children under 15 must be accompanied by an adult to the testing site.

Once at the site, patients should remain in their vehicle and proceed to a designated site located in the parking lot. In rare occasions, the test will take place inside the store, so follow signage and instructions.

"Access to rapid-result tests enables us to help minimize community spread of COVID-19 by being able to more quickly identify active COVID-19 infection," says Dr. David Fairchild, chief medical officer at MinuteClinic, in a news release. "In addition, we can test and treat symptomatic patients who test negative for COVID-19 for seasonal illnesses such as flu or strep and provide appropriate treatment and care."

Earlier this year, CVS expanded its COVID-19 response with drive-thru service in 33 states across the U.S., including Texas. The company's latest offering comes amid a nationwide spike in coronavirus cases, including 500,000 new cases in the last week alone. As of October 26, Texas had more than 874,000 confirmed cases and 17,595 deaths.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.